Charles River Labs up on biologics services

By Staff Reporter

- Last updated on GMT

Image: iStock/patpitchaya
Image: iStock/patpitchaya

Related tags: Contract research organization

Charles River Laboratories says it is positioning itself to take advantage of growing demand for biological services.

The contract research organisation (CRO) reported its full year 2016 results this week, and attributed its $100m – a 13% year-on-year organic increase – in manufacturing revenues to “robust growth”​ in its microbial solutions and biologics testing business.

“Our continued investment in expanding our biologics portfolio, most recently with the acquisition of Blue Stream​, has enabled us to provide a comprehensive portfolio of both bioanalytical and biosafety testing services, with the ability to support biologic and biosimilar development from discovery through clinical phases and commercial manufacturing,”​ CEO James Foster told investors.

“This has increased the value proposition for our clients. And as demand for our services grows, we have added capacity, especially in the US.”

He added the firm views its biologics business is growing in precedence due to the growing number of biologic drugs in development.

“Our goal is to be well-positioned to capitalize on this expanding opportunity, which we believe will support our growth in the coming years.”

For the full year, Charles River reported total revenue of $1.7bn, up 23% year-on-year. The bottom line too was up 4% to $155m.

Related news

Related products

show more

Microaerobic Fermentation of Lactobacillus acidophilus

Microaerobic Fermentation of Lactobacillus acidophilus

Eppendorf for Bioprocess – Solutions that grow with you | 01-Oct-2019 | Application Note

We successfully performed microaerobic fermenta¬tion of a probiotic strain, Lactobacillus acidophilus, at a very low oxygen level, representing the natural...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us

Products

View more

Webinars